Biomerica, Inc. (NASDAQ:BMRA – Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.47 and traded as low as $0.30. Biomerica shares last traded at $0.33, with a volume of 59,303 shares traded.
Biomerica Stock Down 3.0 %
The firm has a 50 day simple moving average of $0.35 and a 200-day simple moving average of $0.46. The stock has a market cap of $5.01 million, a P/E ratio of -0.80 and a beta of -1.11.
Biomerica (NASDAQ:BMRA – Get Free Report) last issued its quarterly earnings results on Tuesday, October 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $1.81 million for the quarter. Biomerica had a negative return on equity of 69.21% and a negative net margin of 110.44%.
Institutional Trading of Biomerica
Biomerica Company Profile
Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.
See Also
- Five stocks we like better than Biomerica
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- How is Compound Interest Calculated?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Most active stocks: Dollar volume vs share volume
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.